The KRAS-G12D mutation drives venous thromboembolism (VTE) and colorectal cancer progression via MAPK/ERK signaling
Our findings establish KMCG as a novel biomarker integrating thrombotic risk and tumor progression, while mechanistically linking KRAS-G12D-driven MAPK activation to both cancer metastasis and thrombosis. This dual regulatory axis provides therapeutic targets for simultaneously managing thrombotic complications and malignant progression in KRAS-mutant CRC.
Authors
- Ming Xu (ORCID: https://orcid.org/0000-0001-8846-2880)
- Jieqi Mao
- Yang Shen (ORCID: https://orcid.org/0000-0002-4682-4852)
- Mei Wang (ORCID: https://orcid.org/0009-0001-4916-3789)
- Dapeng Li (ORCID: https://orcid.org/0000-0002-1816-3217)
- Ziyan Zhu (ORCID: https://orcid.org/0000-0002-2069-5001)
- Jikun Li (ORCID: https://orcid.org/0000-0001-5613-3222)
- Xu Li
- Yichao Du
Institutions
- Shanghai Medical College of Fudan University (CN)
- Shanghai First People's Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1016/j.tranon.2025.102529
- Citations
- 1
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.87